Delafloxacin may provide a feasible alternative antibiotic monotherapy option for treating patients with community-acquired bacterial pneumonia (CABP) who have renal impairment in both inpatient and outpatient settings.
The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.
The Food and Drug Administration (FDA) has approved Fetroja (cefiderocol; Shionogi) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative…
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). Aztreonam is a monobactam that has activity against metallo β-lactamase…
The ability of direct-acting antivirals to eradicate hepatitis C influenced every chapter of the updated 2018 guideline, according to the work group responsible for the revisions.
Kidney transplant recipients who received an HCV-infected kidney had similar allograft function at 1 year to those receiving an uninfected kidney: 66.3 vs 67.1 mL/min/1.73m2, respectively.
A recently published report describes the case of a 33-year-old female patient with HIV who experienced ritonavir-induced nephrolithiasis 2 years after discontinuing the medication.
Likelihood of working higher if symptoms less severe and on illness onset date versus subsequent days
In a study, hepatitis C patients with stage 3 CKD and no diabetes experienced 4.3- and 1.8-fold improvements in eGFR, respectively, with antiviral therapy.
Guidelines include preplacement TB risk assessment, postexposure symptom evaluation and testing
